Grammy winner Lizzo shared a vulnerable video detailing a difficult day in her weight loss journey and reminded her followers ...

Demand forweight-loss drugs has grown at an astonishing rate in recent years, driving share prices of healthcare giants such ...

Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop ...

Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales.

Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen over the high price of the company’s diabetes and obesity drugs, Ozempic ...

Two naturally occurring molecules could be the key to sustained weight management, offering an organic alternative to ...

U.S. representative from Austin asks Health and Human Services secretary to push for generic licensing of semaglutide ...

Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...